FY2025 EPS Estimates for Omnicell Boosted by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Equities researchers at Zacks Research increased their FY2025 earnings per share (EPS) estimates for shares of Omnicell in a note issued to investors on Tuesday, July 15th. Zacks Research analyst R. Department now anticipates that the company will earn $0.31 per share for the year, up from their previous estimate of $0.28. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q4 2025 earnings at $0.17 EPS.

A number of other equities research analysts have also commented on OMCL. Wells Fargo & Company restated an "overweight" rating and set a $37.00 price target (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. JPMorgan Chase & Co. decreased their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Bank of America increased their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Finally, Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Price Performance

NASDAQ OMCL traded down $1.09 during trading hours on Thursday, reaching $26.88. 621,402 shares of the company's stock were exchanged, compared to its average volume of 562,433. The stock has a market cap of $1.26 billion, a PE ratio of 58.44, a price-to-earnings-growth ratio of 8.11 and a beta of 0.76. Omnicell has a one year low of $22.66 and a one year high of $55.75. The firm has a fifty day moving average of $29.08 and a 200-day moving average of $34.30. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same period in the prior year, the company posted $0.03 EPS. The company's revenue was up 9.5% compared to the same quarter last year.

Institutional Trading of Omnicell

Several hedge funds have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. bought a new position in Omnicell during the 4th quarter worth about $37,000. GAMMA Investing LLC increased its holdings in Omnicell by 37.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after purchasing an additional 458 shares in the last quarter. Headlands Technologies LLC bought a new position in Omnicell during the 4th quarter worth about $53,000. Huntington National Bank increased its holdings in Omnicell by 236.4% during the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after purchasing an additional 955 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in Omnicell during the 4th quarter worth about $101,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.